3 results on '"Álvaro Cobo-Calvo"'
Search Results
2. Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
- Author
-
Ana Zabalza, Georgina Arrambide, Susana Otero-Romero, Agustín Pappolla, Paula Tagliani, Samuel López-Maza, Simón Cárdenas-Robledo, Juliana Esperalba, Candela Fernández-Naval, Monica Martínez-Gallo, Mireia Castillo, Mercè Bonastre, Mireia Resina-Salles, Jordina Bertran, Marta Rodriguez-Barranco, Pere Carbonell-Mirabent, Marina Gonzalez, Miguel Merchan, Ana Quiroga-Varela, Albert Miguela, Imma Gómez, Gary Álvarez, René Robles, Dúnia Perez del Campo, Xavier Queralt, Maria José Soler, Irene Agraz, Fernando Martinez-Valle, Breogán Rodríguez-Acevedo, Luciana Midaglia, Ángela Vidal-Jordana, Álvaro Cobo-Calvo, Carmen Tur, Ingrid Galan, Joaquín Castillo, Jordi Río, Carmen Espejo, Manuel Comabella, Carlos Nos, Jaume Sastre-Garriga, Lluís Ramió-Torrentà, Mar Tintoré, and Xavier Montalban
- Subjects
COVID-19 Vaccines ,Multiple Sclerosis ,Neurology ,SARS-CoV-2 ,Vaccination ,COVID-19 ,Humans ,Neurology (clinical) ,Antibodies, Viral - Abstract
Background: The effect of disease-modifying therapies on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response is unclear. Objectives: We aim to determine the immunological responses to SARS-CoV-2 in multiple sclerosis (MS) and anti-CD20-treated patients with other autoimmune diseases (AID). Methods: Humoral and cellular responses we determined before and 30-90 days after vaccination in patients with MS and anti-CD20-treated patients with other AID in two Catalan centers. Results: 457 patients were enrolled. Findings showed that humoral response decreased under anti-CD20s or sphingosine 1-phosphate receptor modulators (S1PRM) and with longer treatment duration and increased after 4.5 months from the last anti-CD20 infusion. Cellular response decreased in S1PRM-treated. Patients on anti-CD20 can present cellular responses even in the absence of antibodies. Conclusion: Anti-CD20s and S1PRM modify the immunological responses to SARS-CoV-2 vaccines.
- Published
- 2022
3. The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteria
- Author
-
Georgina Arrambide, Carmen Espejo, Pere Carbonell-Mirabent, Romina Dieli-Crimi, Marta Rodríguez-Barranco, Mireia Castillo, Cristina Auger, Simón Cárdenas-Robledo, Joaquín Castilló, Álvaro Cobo-Calvo, Ingrid Galán, Luciana Midaglia, Carlos Nos, Susana Otero-Romero, Jordi Río, Breogán Rodríguez-Acevedo, Mariano Ruiz-Ortiz, Annalaura Salerno, Paula Tagliani, Carmen Tur, Angela Vidal-Jordana, Ana Zabalza, Jaume Sastre-Garriga, Alex Rovira, Manuel Comabella, Manuel Hernández-González, Xavier Montalban, and Mar Tintore
- Subjects
Immunoglobulin kappa-Chains ,Multiple Sclerosis ,Immunoglobulin G ,Oligoclonal Bands ,Humans ,Neurology (clinical) ,Demyelinating Diseases - Abstract
Intrathecal production of kappa free light chains occurs in multiple sclerosis and can be measured using the kappa free light chain index. Kappa free light chain index values can be determined more easily than oligoclonal bands detection and seem more sensitive than the immunoglobulin (Ig)G index to diagnose multiple sclerosis. We assessed the value of oligoclonal bands, kappa free light chain index cut-offs 5.9, 6.6 and 10.61, and IgG index to diagnose multiple sclerosis with prospectively acquired data from a clinically isolated syndrome inception cohort. We selected patients with sufficient data to determine oligoclonal bands positivity, MRI dissemination in space and time, IgG index and sufficient quantities of paired CSF and blood samples to determine kappa free light chain indexes (n = 214). We used Kendall’s Tau coefficient to estimate concordance, calculated the number of additional diagnoses when adding each positive index to dissemination in space and positive oligoclonal bands, performed survival analyses for oligoclonal bands and each index with the outcomes second attack and 2017 MRI dissemination in space and time and estimated the diagnostic properties of oligoclonal bands and the different indexes for the previously mentioned outcomes at 5 years. Oligoclonal bands were positive in 138 patients (64.5%), kappa free light chain-5.9 in 136 (63.6%), kappa free light chain-6.6 in 135 (63.1%), kappa free light chain-10.61 in 126 (58.9%) and IgG index in 101 (47.2%). The highest concordance was between oligoclonal bands and kappa free light chain-6.6 (τ = 0.727) followed by oligoclonal bands and kappa free light chain-5.9 (τ = 0.716). Combining dissemination in space plus oligoclonal bands or kappa free light chain-5.9 increased the number of diagnosed patients by 11 (5.1%), with kappa free light chain-6.6 by 10 (4.7%), with kappa free light chain-10.61 by 9 (4.2%) and with IgG index by 3 (1.4%). Patients with positive oligoclonal bands or indexes reached second attack and MRI dissemination in space and time faster than patients with negative results (P < 0.0001 except IgG index in second attack: P = 0.016). In multivariable Cox models [adjusted hazard ratio (95% confidence interval)], the risk for second attack was very similar between kappa free light chain-5.9 [2.0 (0.9–4.3), P = 0.068] and kappa free light chain-6.6 [2.1 (1.1–4.2), P = 0.035]. The highest risk for MRI dissemination in space and time was demonstrated with kappa free light chain-5.9 [4.9 (2.5–9.6), P < 0.0001], followed by kappa free light chain-6.6 [3.4 (1.9–6.3), P < 0.0001]. Kappa free light chains-5.9 and -6.6 had a slightly higher diagnostic accuracy than oligoclonal bands for second attack (70.5, 71.1 and 67.8) and MRI dissemination in space and time (85.7, 85.1 and 81.0). Kappa free light chain indexes 5.9 and 6.6 performed slightly better than oligoclonal bands to assess multiple sclerosis risk and in terms of diagnostic accuracy. Given the concordance between oligoclonal bands and these indexes, we suggest using dissemination in space plus positive oligoclonal bands or positive kappa free light chain index as a modified criterion to diagnose multiple sclerosis.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.